clopidogrel
Blood and blood forming organs (B01)Blood and blood forming organs (B01) compound in Apimeds Pharmaceuticals US's portfolio. Mechanism: Purinergic receptor P2Y12 antagonist.
- Mechanism
- Purinergic receptor P2Y12 antagonist
pharma · Osteoarthritis of the Knee · Multiple Sclerosis · APUS
Apimeds Pharmaceuticals US
Apimeds Pharmaceuticals US drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Matawan, USA HQ
2020 Founded
3 Employees
Public company Type
APUS · NYSE Ticker
Company details
- Status
- Public
- HQ
- Matawan, USA
- Founded
- 2020
- Employees
- 3
- Programs
- 3
- Drugs
- 2
- Patents
- 0
Apimeds Pharmaceuticals US pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Apimeds Pharmaceuticals US drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Apimeds Pharmaceuticals US in public FDA and regional records.